Repurposed treatment for Drug-resistant Multiple Myeloma and cancer stem cells

Background

Multiple myeloma is a complex and currently incurable malignancy characterized by the abnormal proliferation of plasma cells within the bone marrow. As a highly heterogeneous cancer, it presents significant clinical challenges, driving an urgent need for novel and more effective therapeutic strategies. Beyond multiple myeloma, similar challenges exist in treating other malignancies such as mantle cell lymphoma and prostate cancer. The primary clinical imperative in this field of oncology is to achieve durable remission and improve long-term patient survival rates, which remain elusive despite recent advancements in medical science.

The fundamental problem with current standard-of-care treatments is the inevitable development of drug resistance. Patients frequently become refractory to frontline therapies, including proteasome inhibitors and immunomodulatory drugs. This resistance is largely driven by the survival of rare, stem cell-like tumor subpopulations that possess unique properties allowing them to evade conventional treatments. These quiescent, refractory subclones remain dormant during initial therapy only to drive aggressive disease relapse later. Consequently, existing therapeutic regimens fail to eradicate these resilient cancer stem cells, preventing long-lasting cures and leading to fatal disease progression.

Technology

This therapeutic solution utilizes clofazimine as a standalone agent or combined with proteasome inhibitors and immunomodulatory drugs to treat multiple myeloma and other cancers. Functioning as a peroxisome proliferator-activated receptor gamma agonist, the technology modulates transcriptional activity to trigger the proteasomal degradation of critical survival proteins like p65/NFkB, IRF4, and c-Myc. This molecular pathway induces endoplasmic reticulum stress, autophagy, mitochondrial dysfunction, and reactive oxygen species-dependent apoptosis. Additionally, the treatment can be customized into immediate, controlled, or sustained release dosage forms for oral, parenteral, or topical administration to optimize therapeutic efficacy.

What differentiates this solution is its potent ability to target and eliminate drug-resistant myeloma cells and elusive cancer stem-cell subclones that typically drive disease relapse. Unlike standard therapies, it effectively eradicates quiescent and side population cells while operating entirely independently of aryl hydrocarbon receptor expression. When combined with standard care drugs, it demonstrates remarkable synergistic cytotoxicity, significantly reducing the required doses of those medications. By repurposing a well-characterized, FDA-approved medication, this approach provides a highly cost-effective and rapid pathway to clinical translation, offering a critical new strategy for patients with treatment-refractory malignancies.

Benefits

• Overcomes Drug Resistance: Effectively treats multiple myeloma and other cancers that have become refractory to standard therapies, such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs).
• Targets Cancer Stem Cells: Actively reduces and kills dormant cancer stem-cell subpopulations, addressing a primary cause of disease relapse and promoting more durable remissions.
• Enhances Standard Therapies: Demonstrates synergistic cytotoxicity when combined with existing cancer drugs, allowing for lower doses of standard medications which can minimize adverse side effects and toxicity.
• Accelerated Clinical Translation: Repurposes clofazimine, an already FDA-approved and well-characterized drug, providing a faster and highly cost-effective pathway to clinical use.
• Multi-Pathway Tumor Destruction: Employs a robust mechanism of action that induces cellular stress, autophagy, and reactive oxygen species (ROS)-dependent apoptosis while downregulating key survival proteins in cancer cells.
• Highly Flexible Administration: Can be formulated into various dosage forms (immediate, controlled, sustained, delayed, or pulsatile release) for oral, parenteral, or topical delivery, allowing for customizable patient treatment regimens.

Applications

• Drug-resistant multiple myeloma treatment
• Myeloma combination therapy development
• Cancer stem cell targeted therapy
• Mantle cell lymphoma treatment
• Prostate cancer therapeutic formulation

Additional info

This technology comprises pharmaceutical compositions of clofazimine, alone or combined with proteasome inhibitors and immunomodulatory drugs, to treat multiple myeloma and other cancers. Clofazimine acts as a PPARγ agonist, inducing proteasomal degradation of survival proteins like p65/NFkB, IRF4, and c-Myc. This triggers endoplasmic reticulum stress, autophagy, mitochondrial dysfunction, and ROS-dependent apoptosis, targeting drug-resistant cells and cancer stem-cell subpopulations independently of aryl hydrocarbon receptor expression.